

# THE IMPACT FACTOR

## IN THIS ISSUE...



RESEARCH METRICS



NEW EQUIPMENT



GROUP HIGHLIGHTS

### THE IMPACT FACTOR

The Impact Factor is a monthly newsletter highlighting the achievements of the BHI's researchers.

We want to celebrate your success, so please email news and updates to: [bhireport@adelaide.edu.au](mailto:bhireport@adelaide.edu.au)



Dr Basil Hetzel's research linking iodine deficiency with intellectual disability and deformities in infants remains of global significance and an inspiration for today's researchers.



## 2023 IN REVIEW...

2023 was a year of growth for the BHI and we continue to be impressed by the outstanding achievements and success of our researchers.



560+ Publications



121 Grants



27M+ Revenue



80+ Researchers



100+ Students



25+ Research Groups



The Hospital Research Foundation Group provided over \$175,000 in funding for state-of-the-art medical research equipment including a Q-NRG Metabolic Monitor & Philips Lumify L 12-4 linear array transducer to provide improved outcomes for ageing patients and those with IBD.

# GROUP HIGHLIGHTS

---

Underscoring Prof Beltrame's national leadership in advancing cardiovascular research, he was invited to Chair the Clinical and Surgical Stream for the Cardiac Society of Australia and New Zealand (CSANZ) Conference.

## **TVFRC**

Prof Rob Fitridge and colleagues led a successful \$2.27M MRFF grant to support the development and testing of advanced telemedicine for lower-limb complications through Augmented Reality.

## **Vascular Surgery Group**

The group's dedication to raising breast density awareness was reported in The Advertiser & on Channel 10. BreastScreen SA has become the first state to report breast density category to all their clients.

## **Breast & Biology Cancer Unit**

The MITU group coordinates the state-wide NET multi-disciplinary meeting to provide individualised management plans for NET patients in SA and NT. TQEH continues to be the only SA site to provide this service to SA/NT patients with metastatic NET.

## **Molecular Imaging & Therapy Unit (MITU)**

Ms Mirabel Alonge's work confirmed that transplanted kidneys have a lower ability to adapt to the physiological changes that occur in pregnancy. The results of the group's pilot study were presented at a 2023 national scientific meeting.

## **Clinical Pharmacology**

The behavioural change intervention (AVOID) leverages technology to promote behaviour change and brings to Australia for the first time, an innovative program developed and operationalised in 3 cities in Canada.

## **Adelaide Geriatrics Training & Research with Aged Care (GTRAC)**

Professor Peake is a chief investigator for The TARGET Protein trial (NHMRC Funded). It is the largest randomised controlled trial to investigate the administration of enteral protein in critically ill patients.

## **Intensive Care Medicine Research Group**

Research on euglycaemic diabetic ketoacidosis (DKA) led to the Australian Diabetes Society subsequently publishing periprocedural guidelines to mitigate the risk of euglycaemic DKA occurring at the time of colonoscopy.

## **Diabetes & Endocrinology**

DOgSS preliminary findings were platform-presented by Affiliate Associate Professor Anne Hamilton-Brue at the Animal Therapies Ltd and a protocol subsequently published.

## **Stroke Research Programme**

Dr Gaget received a MRFF grant on using faecal transplant to treat patients with pancreatic cancer. This world-first pilot phase I clinical trial is set to start in 2024 at three sites across two states.

**Surgical Science  
Research Group**

A/Prof Rob Bryant was awarded the Michell McGrath Fellowship for the research stream exploring microbial manipulation in IBD.

**Inflammatory Bowel  
Disease**

The Rheumatoid Arthritis Clinical Care Standards Project was led by Professor Catherine Hill. The standards were developed through a collaborative effort involving a multidisciplinary working group in consultation with Arthritis Australia.

**Rheumatology**

Research has yielded a ground-breaking technology poised to significantly enhance the effectiveness of T cell-based adoptive immunotherapy for HER2-positive breast cancer.

**Breast Cancer Research Unit**

Research in the group's lab has shown that zinc may play an important role in maintaining normal function of blood vessels, resulting in a new clinical trial of zinc in treating heart disease.

**Zinc & Cardiovascular Disease  
Research Group**

Katharina Richter was the recipient of the Women in MedTech Champion Award 2023, Medical Technology Association of Australia.

**The Richter Lab**

Approx. 1 in 3 patients who present for total knee replacement in Australia are likely to be on opioid-related pain relief. The group was successful in obtaining a research grant to implement a pathway to wean opioid medications before knee replacement.

**Anaesthesia**

As the only centre in SA with EndoFLIP technology, the research led by Dr Jenny Myers PhD, was disseminated during invited speaker educational sessions (SA, QLD, NSW) and local teaching sessions (BHI).

**Oesophageal Physiology Group**

Highlighting the diversity of the group's research, they report 4x high impact publications for 2023 including Lancet Psychiatry. A/Prof Tibrewal also led a high-impact commentary on a novel hypothesis for the role of glutamate transmission in antipsychotic supersensitivity.

### **Psychiatry**

The group made substantial progress toward harnessing sequencing technologies to develop novel treatments for CRS.

They also set up a custom built "BHInion" workstation allowing BHI to become a fully independent centre of sequencing excellence.

### **ENT**

The group presented their research at the Wold Sleep Conference (Rio de Janiero), Sleep and Breathing Conference (Auckland) and won a New Investigator Award at the Wold Sleep Conference.

### **Respiratory**

The group gathered data from COVID19 convalescents and Long COVID sufferers that identifies a potential biomarker of Long COVID and could lead to the development of a new diagnostic tool in collaboration with SA Pathology.

### **Viral Immunology**

A novel pilot trial enrolling patients for neoadjuvant PIPAC in the setting of high-risk stomach cancers has now been extended to all gastric cancer patients.

### **Peritoneal Cancer Research Group**

Prof Price was invited to talk at the ESMO Asia meeting in October 2023 summarising the current data on G12C mutation agents and their impact on colorectal cancer outcomes.

### **Solid Tumour Group**



If you would like to contribute to The Impact Factor, please contact Brooke Sivendra.

[bhireport@adelaide.edu.au](mailto:bhireport@adelaide.edu.au)